The differential clinical impact of human coronavirus species in children with cystic fibrosis.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 22459737.
- Also identified by DOI 10.1093/infdis/jis274 and PMC identifier 7107351.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated the clinical impact of human coronaviruses (HCoV) OC43, 229E, HKU1 and NL63 in pediatric patients with cystic fibrosis (CF) during routine and exacerbation visits. A total of 408 nasopharyngeal aspirate samples were obtained from 103 patients over a 1-year period. Samples positive for HCoV were submitted for nucleotide sequencing to determine the species. Nineteen samples (4.65%) were positive for HCoV, of which 8 were positive for NL63, 6 for OC43, 4 for HKU1, and 1 for 229E. Identification of HCoV was not associated with an increased rate of respiratory exacerbations, but NL63-positive patients had higher exacerbation rates than patients who were positive for other HCoV species.
Medical subject headings
- Coronavirus
- Coronavirus Infections
- Cystic Fibrosis